Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
InnoCare Pharma OCF Yield % Related Terms
InnoCare Pharma OCF Yield % Historical Data
* Premium members only.
The historical data trend for InnoCare Pharma's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:09969 vs VRTX, REGN, RVMD: OCF Yield % Comparison
For the Biotechnology subindustry, InnoCare Pharma's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCare Pharma OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, InnoCare Pharma's OCF Yield % distribution charts can be found below:
* The bar in red indicates where InnoCare Pharma's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InnoCare Pharma (HKSE:09969) has a OCF Yield % of 0.30 as of Aug. 23, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on InnoCare Pharma and its competitors. According to the industry distribution chart, InnoCare Pharma ranks #284 out of 1410 companies in the Biotechnology industry, placing it in the top 20.1%.
Is InnoCare Pharma's OCF Yield % too high?
InnoCare Pharma's current OCF Yield % is 0.30. Based on the distribution chart, InnoCare Pharma ranks #284 out of 1410 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, InnoCare Pharma has a GF Score™ of 83/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCare Pharma's OCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, InnoCare Pharma ranks #284 out of 1410 companies for OCF Yield %. This places InnoCare Pharma in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on InnoCare Pharma and its competitors. InnoCare Pharma's current OCF Yield % is 0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCare Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCare Pharma (HKSE:09969) is currently considered Possible Value Trap. The stock's GF Value™ is HK$21.38, compared to a current price of HK$14.27 — trading 33.3% below its estimated fair value. The current OCF Yield % is 0.30. InnoCare Pharma's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For InnoCare Pharma (HKSE:09969), the current OCF Yield % is 0.30 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCare Pharma (HKSE:09969) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCare Pharma stock appears to be undervalued.
The current stock price of HK$14.27 is trading 33.3% below its estimated GF Value™ of HK$21.38.
GuruFocus considers InnoCare Pharma to be Possible Value Trap.
Key valuation signals for HKSE:09969:
OCF Yield %: 0.30
GF Value™: HK$21.38 vs. price of HK$14.27 (33.3% below fair value)
No single metric tells the full story. See the HKSE:09969 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
83GF Score
Get the complete analysis for HKSE:09969
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:09969 has been successfully added to your 
